<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>27061663</identifier>
<setSpec>1699-7980</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Cózar-Olmo, J</dc:author>
<dc:author>Gómez-Veiga, F</dc:author>
<dc:author>Burgos-Revilla, J</dc:author>
<dc:author>Alcaraz-Asensio, A</dc:author>
<dc:description xml:lang="en">OBJECTIVE To review the latest evidence on the oncologic urology of prostate, renal and bladder tumours, analysing their impact on daily clinical practice and future medium to long-term regimens. METHODS We review the abstracts on prostate, renal and bladder cancer presented at the 2015 congresses (EAU, AUA, ASCO, ESMO y ASTRO) that received the best evaluations by the OncoForum committee. RESULTS Cabozantinib could represent a new second-line (or subsequent) treatment option for patients with advanced renal cancer. In muscle-invasive bladder cancer, the genetic expression profile could predict the clinical benefit of neoadjuvant therapy in treating urothelial tumours. In metastatic castration-resistant prostate cancer, results were presented from various studies that evaluated the addition of chemotherapy to standard treatment with androgen deprivation, showing a reduction in the progression risk and higher PSA response rates. CONCLUSIONS New options for the second-line treatment of renal cancer were presented. In metastatic castration-resistant prostate cancer, various studies have been published on treatment with enzalutamide, which has been shown to delay the symptomatic disease and benefit overall survival.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Cáncer de próstata</dc:subject>
<dc:subject>Renal cancer</dc:subject>
<dc:subject>Cáncer renal</dc:subject>
<dc:subject>Cáncer de vejiga</dc:subject>
<dc:subject>Oncourología</dc:subject>
<dc:subject>Urooncología</dc:subject>
<dc:subject>Bladder cancer</dc:subject>
<dc:subject>Prostate cancer</dc:subject>
<dc:subject>Urologic oncology</dc:subject>
<dc:subject>Oncologic urology.</dc:subject>
<dc:date>2016 Jul-Aug </dc:date>
<dc:title xml:lang="es">Avances en uro-oncología «OncoForum»: lo mejor de 2015.</dc:title>
<dc:title xml:lang="en">Developments in urologic oncology «OncoForum»: The best of 2015.</dc:title>
<dc:publisher>Actas urologicas espanolas</dc:publisher>
</metadata>
</record>
</pubmed-document>
